-
Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository
•
Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has finalized an acquisition of a mesalazine suppository product from Jiangsu Anbison Lab. This product is indicated for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. The financial details and other…
-
China’s Pharma Firms Collaborate on Generic Version of Sun Pharma’s Carbamazepine
•
Several China-based pharmaceutical companies, including Shanghai Zhongxi Sunve Pharmaceutical Co. Ltd, Shanghai Anbison Lab Co., Ltd, Qingdao BAHEAL Pharmaceutical Co., Ltd, and SPH Pharmaceutical Sales Co., Ltd, have agreed to collaborate on the development and marketing of Anbison Lab’s first generic version of carbamazepine sustained-release tablets (II) in China. The…
